Limitless flags new customs rules for international pharmacy sourcing

Limitless Consulting Group says new U.S. customs actions could disrupt international pharmacy sourcing for self-funded employer health plans by changing importer-of-record rules, adding entry requirements and increasing parcel costs and delays. The firm is offering employers a free review of their sourcing programs and a repriced estimate across nine channels.

Why it matters: - Self-funded employer health plans that rely on international pharmacy sourcing may face higher fixed customs costs and slower delivery times for filled prescriptions. - The changes could hit low-cost medications hardest because the new parcel-level costs are not tied to drug price. - Employers with 90-day fills have a limited window to understand how their vendor’s shipping model will be affected before late-November rule changes.

What happened: - Limitless Consulting Group published a white paper, Executive Order 14411: International Sourcing Overview and Impact 2026, and a short film on what the order means for employer health plans. - The firm is offering employers a complimentary review of their current international sourcing program, with results returned in 1 to 3 business days. - Executive Order 14411, signed June 3, 2026, changes importer-of-record eligibility, border entry responsibilities, bond requirements and the use of simplified informal entry for direct-to-member parcels. - The 180-day provisions on importer eligibility and vetting are due Nov. 30, 2026. - U.S. Customs and Border Protection published an interim final rule on June 24, 2026 that suspended the de minimis exemption for international mail. - The new postal informal entry process excludes merchandise subject to partner government agency requirements as of Oct. 22, 2026. - FDA data requirements make prescription drugs subject to that exclusion.

The details: - Limitless says international sourcing typically moves prescriptions from a foreign pharmacy to a U.S. member as a low-value parcel. - The white paper says three sourcing structures dominate the market: the foreign pharmacy or consolidator acts as importer of record, a U.S. entity owned by the foreign operator signs for the parcel, or the member serves as importer while a vendor coordinates shipment. - The first two models must change how the parcel enters the country. - The member-import model keeps its structure, but its cost and timeline change. - Limitless says it included 10 questions plan sponsors should ask their current vendor in writing. - The Pharmacy Stewardship Program prices every medication across nine optimized sourcing channels and identifies the lowest net-cost route for each member. - Limitless does not source, import or dispense medications. - Licensed vendors hold the sourcing relationships and shipping obligations. - If a vendor’s international parcel route changes, the same drug may have a domestic alternative through a biosimilar, cash price, manufacturer or charitable foundation program, a 340B pharmacy or a group purchasing contract. - Limitless also compares plan claims against published Cost Plus Drugs and TrumpRx lists to identify where a published price is below what the plan paid on the same fill. - The pharmacy benefit manager, network and formulary remain in place, and the plan document is not amended. - Limitless is paid out of documented savings, and the fee is disclosed. - The published list is strongest on generics and a defined set of biosimilars. - Limitless says some plans paying more than $10,000 per fill for a branded biologic may find published prices in the hundreds of dollars. - The complimentary review starts with the vendor’s most recent savings report or a list of the plan’s 25 highest-cost medications. - Limitless prices each line across all nine channels and shows what is preserved, what moves to a domestic route and what changes for the member. - When the current vendor’s price is better on a line, the analysis says so. - The employer’s benefits consultant leads the engagement. - There is no fee and no obligation. - To request the white paper or review, employers can visit more information, email Support@LimitlessRxSolutions.com or call (719) 789-2268.

Between the lines: - Limitless is positioning the rule changes as a market shakeup that could push consolidation across international pharmacy sourcing. - The company is also framing its service as a fallback plan for employers that may lose access to current international routing options. - The new rules may force plan sponsors to compare international sourcing against domestic pricing and alternative channels more aggressively.

What's next: - Plan sponsors have about one quarter to determine whether their current vendor can still deliver under the new entry rules. - Employers with January renewals will be among the first to operate entirely under the updated framework. - Limitless says sponsors should ask vendors now how their parcels will enter the country while a full refill cycle remains before Nov. 30, 2026. - The firm says employers and consultants are seeking ways to preserve savings on high-cost medications as vendors adjust to the new rules.